The factors predicting pneumonia in COVID-19 patients: preliminary results from a university hospital in Turkey

Özger, Hasan Selçuk; Yıldız, Pınar Aysert; Gaygısız, Ümmügülsüm; Dikmen, Asiye Uğraş; Gulmez, Zehra Demirbas; Yi̇ldi̇z, M.; Şenol, Esin; Hızel, Kenan; Tunçcan, Özlem Güzel; Çağlar, Kayhan; Bozdayı, Gülendam; Köktürk, Nurdan; Çiftçi, Tansu Ulukavak; Bikmaz, Sahender GÜlbIn Aygencel; Türkoğlu, Melda; Aydoğdu, Müge; Karabiyik, Lale; Tufan, Abdurrahman; Erbaş, Gonca; Kılıç, Hüseyin; Keleş, Ayfer; Bildik, Fikret; Kılıçaslan, İsa; Karamercan, Mehmet Akif; Aslaner, Mehmet Ali; Demircan, Ahmet; Kavutçu, Mustafa; Gülbahar, Özlem; Arhan, Mehmet; Bostancı, Hasan; Tutar, Hakan; Dündar, Nazlıhan Boyaci; Oğuzülgen, I. Kıvılcım; Dizbay, Murat

doi:10.3906/sag-2005-385

Cited by 16 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[13][14][15]23 58.7% of our patients had at least one accompanying comorbidity. The most common one was HT in our study, compatible with the other studies, 3,4,12,13,18,20,24 followed by DM, 3,5,12,13,19,20 and cardiovascular diseases. 5 Obesity was one of the comorbidities reported to affect disease severity and mortality, 4,5,20 but could not be determined in this retrospective study.…”

Section: Discussionsupporting

confidence: 92%

“…The incidence of COPD and asthma was lower in our patients (5.9% and 8.9%, respectively), as in the other studies. [2][3][4][5]12,18,26 Fever and cough were frequently reported initial symptoms [2][3][4]12,19,20,25,26 , similarly the most common presenting symptom was cough in this study. Dyspnea on admission was observed in 32% of our patients, as mentioned in other studies.…”

Section: Discussionsupporting

confidence: 52%

“…Previously reported studies among patients with COVID-19 have stated predominance of older age and male sex, particularly in hospitalized patients. 2,4,5,[12][13][14][15][16][17][18][19][20][21][22] Similarly, 55.5% of our patients were male and the median age was 57.…”

Section: Discussionmentioning

confidence: 97%

“…Older age, male sex and comorbidities were significantly associated with the severity of the disease and mortality. 2,4,5,[13][14][15][16][17][18][19][20][21][22][23] It has been reported that 13-73.4% of the patients had comorbidities. [13][14][15]23 58.7% of our patients had at least one accompanying comorbidity.…”

Section: Discussionmentioning

confidence: 99%

“…The rate of patients who needed intensive care has been reported to be 5-15.7% in different studies. 2,3,18,22,25,41,42 Mortality varies from 2.08% to 78% in patients with COVID-19 disease 12,14,15,21,24,41,42 , and from 1.4% to 72% among ICU patients with COVID-19. 3,4,16,17,27 In the studies conducted in our country, mortality rates between 2.08 and 10.5% 26,27,41,42 have been reported.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Assessment and management of the SARS-CoV-2 infection: A secondary center experience

Yardımcı

Ergen

Yıldız

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The aim of the study was to evaluate the management and outcomes of the patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a secondary hospital. Methods: A total of 699 hospitalized patients who had positive rRT-PCR for SARS-CoV-2 and/or typical findings of COVID-19 at chest computed tomography (CT) were enrolled in this study. Demographics, comorbities, initial laboratory tests on admission, treatment modalities, complications and outcomes were evaluated retrospectively. Results: The mean age was 57.0±15.6 (range:16-94 years), and male:female ratio was 1.24. 58.7% of the patients had at least one underlying comorbidity, the most common was hypertension. 72.8% of the patients had positive RT-PCR. 18.1% of the patients had lymphopenia, 35.7% hyperferritinemia, 58.3% increased lactate dehydrogenase, and 58.5% increased D-dimer. Chest CT revealed moderate and severe stage in 57.9% of the patients, and bilateral lung involvement in 78.7%. Hydroxychloroquine was given to 37.2% and favipiravir 67.1% of the patients. No significant difference was observed between treatment groups in terms of mortality (P=0.487). 5.8% of the patients were transferred to the ICU, of whom 75.6% were needed non-invasive and 36.5% invasive mechanical ventilation. The overall case fatality rate was 0.9. Conclusions: Older age, male sex, low lymphocyte count, CT findings including bilateral involvement and severe stage were significantly associated with poor prognosis and mortality.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Assessment and management of the SARS-CoV-2 infection: A secondary center experience

Yardımcı

Ergen

Yıldız

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Its all about IFN‐λ4: Protective role of IFNL4 polymorphism against COVID‐19‐related pneumonia in females

Matic,

Milovanovic,

Mijailovic

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Despite the pivotal role of IFN‐λs in the innate immune response, the data on its genetic polymorphism in relation to COVID‐19 severity are scarce and contradictory. In the present study, we aimed to determine if the presence of the most frequent functional single nucleotide polymorphisms (SNPs) of the two most important IFN‐λs coding genes, namely IFNL3 and IFNL4, alters the likelihood of SARS‐CoV‐2‐infected patients to develop more severe form of the disease. This observational cohort study involved 178 COVID‐19 patients hospitalized at the University Clinical Centre Kragujevac, Serbia. Patients' demographics, clinical characteristics, and laboratory parameters were collected at admission. COVID‐19 signs and symptoms were assessed during the hospital stay, with the worst condition determining the disease severity. Genotyping for IFNL3 (rs12980275 and rs8099917) and IFNL4 (rs12979860 and rs368234815) SNPs was conducted using TaqMan assays. Our study revealed carriers of IFNL3 and IFNL4 minor alleles to be less likely to progress from mild to moderate COVID‐19, that is, to develop COVID‐19‐related pneumonia. After adjustment for other factors of influence, such as age, sex, and comorbidities, the likelihood of pneumonia development remained significantly associated with IFNL4 polymorphism (odds ratios [ORs] [95% confidence interval (95% CI)]: 0.233 [0.071; 0.761]). When the patients were stratified according to sex, the protective role of IFNL4 minor alleles, controlled for the effect of comorbidities, remained significant only in females (OR [95% CI]: 0.035 [0.003; 0.408]). Our results strongly suggest that IFNL4 rs12979860 and rs368234815 polymorphisms independently predict the risk of COVID‐19‐related pneumonia development in females.

show abstract

Development and validation of models for two‐week mortality of inpatients with COVID‐19 infection: A large prospective cohort study

Fathi

Markazi-Moghaddam

Kheyrati

2022

Statistical Analysis

View full text Add to dashboard Cite

Recognizing COVID-19 patients at a greater risk of mortality assists medical staff to identify who benefits from more serious care. We developed and validated prediction models for two-week mortality of inpatients with COVID-19 infection based on clinical predictors. A prospective cohort study was started in February 2020 and is still continuing. In total, 57,705 inpatients with both a positive reverse transcription-polymerase chain reaction test and positive chest CT findings for COVID-19 were included. The outcome was mortality within 2 weeks of admission. Three prognostic models were developed for young, adult, and senior patients. Data from the capital province (Tehran) of Iran were used for validation, and data from all other provinces were used for development of the models. The model Young, was well-fitted to the data (p < 0.001, Nagelkerke R 2 = 0.697, C-statistics = 0.88) and the models Adult (p < 0.001, Nagelkerke R 2 = 0.340, C-statistics = 0.70) and Senior (p < 0.001, Nagelkerke R 2 = 0.208, C-statistics = 0.68) were also significant. Intubation, saturated O 2 < 93%, impaired consciousness, acute respiratory distress syndrome, and cancer treatment were major risk factors. Elderly people were at greater risk of mortality. Young patients with a history of blood hypertension, vomiting, and fever; and adults with diabetes mellitus and cardiovascular disease had more mortality risk. Young people with myalgia; and adult patients with nausea, anorexia, and headache showed less risk of mortality than others.

show abstract

The factors predicting pneumonia in COVID-19 patients: preliminary results from a university hospital in Turkey

Cited by 16 publications

References 20 publications

Assessment and management of the SARS-CoV-2 infection: A secondary center experience

Assessment and management of the SARS-CoV-2 infection: A secondary center experience

Its all about IFN‐λ4: Protective role of IFNL4 polymorphism against COVID‐19‐related pneumonia in females

Development and validation of models for two‐week mortality of inpatients with COVID‐19 infection: A large prospective cohort study

Contact Info

Product

Resources

About